ReviewAntiviral research2005
Development of antiviral therapy for severe acute respiratory syndrome.
Review in Antiviral research, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 67 citations in OpenAlex.
- Recent Advances in Antiviral Activities of Triterpenoids.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Article
- SARS-CoV: Lessons learned; opportunities missed for SARS-CoV-2.Reviews in medical virology · 2021Review
- Repurposing Nucleoside Analogs for Human Coronaviruses.Antimicrobial agents and chemotherapy · 2020Article
- COVID-19: Current Developments and Further Opportunities in Drug Delivery and Therapeutics.Pharmaceutics · 2020Review
- Repurposing current therapeutic regimens against SARS-CoV-2 (Review).Experimental and therapeutic medicine · 2020Review
- Layer-By-Layer Nanocoating of Antiviral Polysaccharides on Surfaces to Prevent Coronavirus Infections.Molecules (Basel, Switzerland) · 2020Review
- Potential repurposed SARS-CoV-2 (COVID-19) infection drugs.RSC advances · 2020Review
- Thoughts on What Chemists Can Contribute to Fighting SARS-CoV-2 - A Short Note on Hand Sanitizers, Drug Candidates and Outreach.Angewandte Chemie (International ed. in English) · 2020Article
- Efficacy and safety of chloroquine and hydroxychloroquine for COVID-19: A comprehensive evidence synthesis of clinical, animal, and in vitro studies.Medical journal of the Islamic Republic of Iran · 2020Review
- Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?Frontiers in microbiology · 2020Review
- Review
- Targeting membrane-bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the middle East respiratory syndrome virus.PLoS pathogens · 2014Article
- Chikungunya virus: an update on antiviral development and challenges.Drug discovery today · 2013Review
- Dieckol, a SARS-CoV 3CL(pro) inhibitor, isolated from the edible brown algae Ecklonia cava.Bioorganic & medicinal chemistry · 2013Article
- Development of chemical inhibitors of the SARS coronavirus: viral helicase as a potential target.Biochemical pharmacology · 2012Review
- Human coronaviruses: insights into environmental resistance and its influence on the development of new antiseptic strategies.Viruses · 2012Review
- Traditional Chinese medicine herbal extracts of Cibotium barometz, Gentiana scabra, Dioscorea batatas, Cassia tora, and Taxillus chinensis inhibit SARS-CoV replication.Journal of traditional and complementary medicine · 2011Article
- Interference of ribosomal frameshifting by antisense peptide nucleic acids suppresses SARS coronavirus replication.Antiviral research · 2011Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A new disease, the severe acute respiratory distress syndrome (SARS), caused by the SARS coronavirus (SARS-CoV), emerged at the beginning of 2003 and rapidly spread throughout the world. Although the disease had disappeared in June 2003 its re-emergence cannot be excluded. The development of vaccines against SARS-CoV may take years. Therefore, the availability of effective antiviral drugs against SARS-CoV may be crucial for the control of future SARS outbreaks. In this review, experimental and clinical data about potential anti-SARS drugs is summarised and discussed. Animal model studies will be needed to help to determine which interventions warrant controlled clinical testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.